-
Study aim
-
Study the effect of spray coldamaris in recovery of oral mucositis in SCT patients
-
Design
-
This clinical trial at Ghazi Tabatabaei Hospital in Tabriz involves 50 patients with myeloma, lymphoma, and acute leukemia undergoing bone marrow transplantation. Patients are randomly split into two groups of 25. The intervention group uses FDA-approved coldamaris spray three times daily for one week if mucositis occurs, while the control group receives no treatment. The study evaluates mucositis incidence, severity, and related clinical findings, comparing outcomes between groups.
-
Settings and conduct
-
This clinical trial was conducted on 50 patients with myeloma, lymphoma, and acute leukemia who were hospitalized in the transplant ward of Ghazi Tabatabaei Hospital in Tabriz over one year. After bone marrow transplantation, patients were evaluated for the incidence and severity of mucositis and its association with clinical and paraclinical findings.
The patients were randomly divided into two groups of 25: control and intervention. Patients who developed mucositis in the intervention group used coldamaris spray (FDA-approved, Sec.172.620) three times daily for one week. Their outcomes were compared with the control group, which did not use the spray. The study aimed to compare the outcomes between the two groups.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
Patients with myeloma, lymphoma, and acute leukemia in the HSCT ward of Ghazi Tabatabaei Hospital, Tabriz.
Exclusion criteria:
Patients unwilling to use coldamaris spray, pregnant patients, and patients with unstable hemodynamics.
-
Intervention groups
-
Patients with myeloma,lymphoma, acute leukemia
-
Main outcome variables
-
Severity of oral mucositis based on the WHO scale after the use of Coldamaris spray, duration of recovery, oral feeding status, and requirement for systemic analgesics.